以下文章来源于数据宝 ，作者刘俊伶 本周（11月10日至14日）港股市场主要股指涨跌不一，恒生指数累计上涨1.26%，恒生科技指数下跌0.42%，恒生中 国企业指数上涨1.41%。 据证券时报·数据宝统计，本周南向资金合计成交净流入247.73亿港元，环比下降35.95%， 已连续26周净流入。 从本周上榜每日前十大活跃个股名单来看，共有17只个股上榜， 阿里巴巴-W 本周港股通成交总额最高，达到 489.19亿港元， 中芯国际、腾讯控股 港股通买卖总额均超过200亿港元。 从成交净买入金额来看，大型科技股本周获南向资金买卖不一， 小米集团-W 本周获南向资金净买入金额最高，达 到43.32亿港元，已连续两周居于净买入首位，上周成交净买入43.11亿港元。小米集团 -W9月26日以来走势明显下 跌，累计跌幅近三成。 腾讯控股 本周获南向资金净买入金额8.58亿港元。 阿里巴巴-W、美团-W 遭到南向资金减持，分别净卖出24.79亿港 元、1.92亿港元。 数据宝 . 数据宝——证券时报智能原创新媒体，中国股市大数据新媒体领先品牌，依托证券时报财经数据库和证监会指定信 息披露媒体的权威信息，让您用手机也能从海量 ...

Group 1 - The CITIC Pharmaceutical Index increased by 3.29%, outperforming the CSI 300 Index by 4.37 percentage points, ranking 3rd among 30 primary industries [1] - The top ten stocks with the highest gains this week include Jindike, Renmin Tongtai, Chengda Pharmaceutical, Hefuchina, Fuxiang Pharmaceutical, Te Yi Pharmaceutical, Yao Yigou, Bohui Innovation, Shuyupingmin, and Haichen Pharmaceutical [1] - The top ten stocks with the largest declines this week include *ST Changyao, Zhend Medical, Heyuan Biological-U, Weigao Blood Purification, Furui Shares, Ruimaite, Microelectrophysiology, Botuo Biological, Bibete-U, and Shuoshi Biological [1] Group 2 - On November 10, Guangshentang Pharmaceutical's core drug, the oral small molecule hepatitis B surface antigen inhibitor GST-HG131, had its Phase II clinical data selected for the AASLD annual meeting's latest breakthrough summary and was reported on-site [1] - GST-HG131 is the first oral drug in global hepatitis B clinical breakthrough research that significantly reduces HBsAg in hepatitis B patients, with 76.5% of patients achieving levels below 100 IU/ml within three months, attracting attention from many multinational pharmaceutical companies for potential collaboration [1] Group 3 - On November 10, Roche announced that its third-generation BTK inhibitor Fenebrutinib met primary endpoints in two Phase III studies (FENhance 2 and FENtrepid) for treating relapsing multiple sclerosis (RMS) [2] - Results showed that at week 96, the annualized relapse rate (ARR) for patients on Fenebrutinib was significantly lower compared to those on teriflunomide, and at week 120, Fenebrutinib was non-inferior to Ocrevus in delaying disability progression in primary progressive multiple sclerosis (PPMS) patients [2] - Pfizer announced the successful completion of its $9.2 billion acquisition of Metsera, a biopharmaceutical company focused on developing next-generation treatments for obesity and cardiovascular metabolic diseases [2] - This acquisition adds a series of potential candidates highly complementary to Pfizer's existing internal medicine pipeline, including MET-097i, a weekly or monthly injectable GLP-1 receptor agonist entering Phase III trials, and MET-233i, a monthly amylin analog currently in Phase I evaluation [2]

Core Viewpoint - The article discusses the recent performance and challenges faced by Nuon Fund, highlighting the dramatic rise and fall of its star fund manager, Cai Song Song, and the implications for investors and the fund's future [2][8][30]. Group 1: Fund Performance - In Q3 2025, the public fund industry earned a total profit of 2.08 trillion, a 4.4 times increase compared to the previous quarter, with major firms like E Fund, Huaxia, and Harvest each exceeding 100 billion in profits [2]. - Nuon Fund's growth was significant under Cai Song Song, with its scale expanding from 380 million at the end of 2018 to nearly 33 billion by the end of 2020, an increase of 85 times [8]. - However, the fund suffered a 40.04% decline in 2022, resulting in a loss of 12.93 billion, leading to a drastic change in investor sentiment towards Cai Song Song [8][11]. Group 2: Management Changes and Challenges - Cai Song Song's abrupt resignation in September 2023 was followed by allegations of corruption, which raised concerns about the fund's leadership and future direction [10][11]. - Liu Huiying, who took over after Cai, continues to focus heavily on semiconductor investments, but without the favorable market conditions, this strategy may lead to increased volatility [11][30]. - The fund's assets have decreased from a peak of 33 billion to 18.52 billion, indicating a loss of 14.48 billion in value [13]. Group 3: Governance Issues - The founder of Nuon Fund, Qin Mouzhou, has been implicated in a bigamy case, which has further tarnished the fund's reputation [16][18]. - The fund has faced regulatory scrutiny, including a three-month suspension of ETF product registrations due to internal control failures [19][20]. Group 4: Strategic Direction - Nuon Fund's QDII products have underperformed significantly, with total assets dwindling to 1.014 billion, representing only 0.5% of the company's total scale [22]. - Despite past missteps, the fund has a strong technology research team and a balanced management structure, which may provide opportunities for recovery if volatility can be managed [26][29].

Core Insights - Sanofi Pharmaceutical (01530.HK) has been included in Forbes' "Top 50 Innovative Companies in China 2025," marking it as one of the eight pharmaceutical companies on the list [1] - The evaluation criteria for the list include innovation capability (R&D investment and independent intellectual property), corporate governance, growth potential, market advantages driven by innovation, and social image [1] - This recognition highlights the company's sustained innovation resilience and industry leadership, reflecting the Chinese biopharmaceutical industry's shift towards global value chain leadership through innovation [1] Company Strategy - The company has consistently prioritized innovation as its core development strategy, leveraging opportunities in the high-quality development phase of China's innovative pharmaceuticals [1] - It has made forward-looking investments in cutting-edge fields, launching several self-innovated biological drugs that meet patient needs while promoting industry upgrades [1] - By 2025, the company anticipates a concentrated harvest period for its R&D pipeline, with significant clinical breakthroughs in core areas such as oncology and autoimmune diseases [1] International Expansion - The company's internationalization strategy is accelerating, with notable progress in multiple overseas licensing collaborations, indicating a rising global innovative influence [1] - The recognition from the industry and capital markets underscores the high regard for the company's innovation capabilities and strategic direction [1] - As the global pharmaceutical competitive landscape reshapes and Chinese innovative pharmaceutical companies rise, the company is steadily advancing towards becoming an innovative biopharmaceutical enterprise with a foundation in China and a global outlook [1]

对于市场配置，华泰证券建议维持"哑铃型"配置： 周五（11月14日）沪指冲高回落跌近1%，盘中一度翻红续创10年新高，最终失守4000点，创业板指跌 近3%，沪深两市成交额1.96万亿元，环比缩量839亿元。 受外围市场大跌影响，权重股、题材概念共振下行。市场萎靡之际，银行强势逆袭！工商银行、农业银 行股价再创新高，双百亿顶流银行ETF（512800）场内价格盘中涨近1.2%，刷新2025年8月以来新高。 网友调侃，银行才是"存储龙头"，存款的"存"，储蓄的"储"。 然而A股真正的存储芯片概念则遭遇重挫，算力硬件方向集体回调，CPO等板块跌幅居前。伴随中信证 券发声看好AI，认为算力有望复刻美股长牛行情，资金无惧行情波动，坚定加仓AI，重仓光模块龙头 的创业板人工智能ETF（159363）全天获资金净申购4400万份，重点布局国产AI产业链的科创人工智能 ETF（589520）近10日累计吸金4805万元。 周期风口已至，有色强势领跑！受益于美联储降息周期，新兴产业需求释放，"反内卷"政策护航等多重 利好催化，有色金属板块年内累计上涨75%，板块涨幅高居31个申万一级行业断层第一。展望后市，中 信建投认为，2 ...

Core Insights - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 8.3% this week, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 6.9% [1] - The pharmaceutical sector has shown a significant structural recovery trend after a prolonged period of valuation adjustment, with continued innovation in drug development expected in the second half of the year [1] Index Performance - The weekly performance of various indices is as follows: - Hang Seng Innovative Drug Index: +8.3% - CSI Hong Kong Medical and Health Comprehensive Index: +6.9% - CSI Innovative Drug Industry Index: +2.9% - CSI Biotechnology Theme Index: +2.3% - CSI 300 Medical and Health Index: +1.6% [2] - The rolling P/E ratios for these indices are: - Hang Seng Innovative Drug Index: 60.6x - CSI Hong Kong Medical and Health Comprehensive Index: 29.2x - CSI Innovative Drug Industry Index: 52.2x - CSI Biotechnology Theme Index: 57.3x - CSI 300 Medical and Health Index: 31.8x [2] Valuation Insights - The valuation percentiles as of July 10, 2023, are: - Hang Seng Innovative Drug Index: 46.0% - CSI Hong Kong Medical and Health Comprehensive Index: 76.7% - CSI Innovative Drug Industry Index: 68.7% - CSI Biotechnology Theme Index: 52.3% [2] - The indices have shown varying performance over different time frames, with the Hang Seng Innovative Drug Index up 90.2% year-to-date and 88.8% over the past year [6] ETF Tracking - There is one ETF tracking the Hang Seng Innovative Drug Index, four ETFs for the CSI Hong Kong Medical and Health Comprehensive Index, seven for the CSI Innovative Drug Industry Index, and four for the CSI Biotechnology Theme Index [4]

11月14日，大市深度调整，沪指跌0.97%报收3990.39点，创指跌2.82%尽吐上日涨幅。震荡之际，制药 板块彰显防御力！全市场唯一跟踪制药指数的药ETF（562050）盘中逆市飘红，一度冲高1%，场内最 终微跌0.18%，显著跑赢市场。 药ETF（562050）覆盖50大龙头药企，重仓创新药，兼顾中药。今日中药龙头以岭药业领涨3.14%，同 仁堂亦收红；创新药局部活跃，甘李药业、康弘药业涨约2%。恒瑞医药、百济神州-U、片仔癀等龙头 股下跌为主要拖累。 每年年底是美国生物医药收并购最活跃的季节，且明年年初还有JPM大会催化。今年医保谈判，继续对 创新药"暖风劲吹"，在美联储降息的宏观背景下，当下创新药向上机会或已大于向下风险。 基本面亦频传利好。从已公布的三季报数据来看，创新药板块整体实现业绩回暖，多家公司实现扭亏， 创新药龙头百济神州业绩亮眼，反映出行业正从研发投入期加速迈入商业化收获期。 回归根本逻辑，制药是刚需赛道，未来市场空间巨大。我国作为人口大国，随着老年人口比例的不断上 升，对药品的需求也在持续增长，尤其是慢性疾病治疗药物等领域。此外，随着人们生活水平的提高， 对医疗保健的重视程度也日益增 ...

在全球市场普遍下跌的背景下，A股展现出惊人韧性，沪指盘中翻红续创十年新高，银行股与区域性板块轮番表现，凸显中国市场独特吸引力。 11月14日，A股早间弱势整理，上证指数午盘微跌0.16%，盘中一度翻红续创10年新高，深成指、创业板指均跌超1%。算力硬件产业链领跌，存 储芯片、HBM、CPO方向跌幅居前，有色金属回调，SPD强势上涨。 具体来看，海南自贸区板块逆势大涨，海马汽车、海南海药（维权）等多股涨停。医药商业股拉升，漱玉平民、开开实业等封板。福建本地股反 复活跃，海峡环保、平潭发展等十余股涨停。银行股延续强势，工行、农行股价再创新高。下跌方面，存储芯片板块下挫，佰维存储跌超10%。 A股市场内部则呈现明显的结构性特征，个股涨多跌少，沪深京三市超2800股飘红，半天成交额达1.25万亿元。以下是核心指数情况： 上证指数早盘收报4022.89点，跌0.16%。 深证成指早盘收报13327.91点，跌1.10%。 创业板指早盘收报3146.01点，跌1.74%。 沪深300早盘收报4666.68点，跌0.75%。 科创50早盘收报1378.27点，跌1.50%。 中证500早盘收报7296.48点，跌0.80% ...

Market Overview - The Hong Kong stock market experienced a decline today, with the Hang Seng Index closing at 26,572.46 points, down 500.57 points, representing a drop of 1.85% [2] - The Hang Seng Technology Index also fell, closing at 5,812.80 points, down 168.50 points, a decrease of 2.82% [5] Sector Performance - Technology stocks faced widespread declines, with Baidu Group-SW (09888.HK) dropping over 7%, JD Group-SW (09618.HK) down over 6%, and Alibaba-W (09988.HK) falling over 4% [5] - The lithium battery sector saw significant losses, with Tianqi Lithium (09696.HK) down over 4% and Ganfeng Lithium (01772.HK) down over 3% [5] - Chinese brokerage stocks weakened, with CITIC Securities (06030.HK) declining over 4% [5] - Conversely, the innovative drug sector saw gains, with Gilead Sciences-B (01672.HK) rising over 15%. The innovative drug sector reported a 36% year-on-year revenue growth in Q3, with continued quarter-on-quarter growth [5] Capital Flow - After a small net sell-off of southbound funds yesterday, there was a return of capital today, with a cumulative net purchase of Hong Kong stocks reaching 12.8 billion HKD by the end of the trading day [6] Future Outlook - Western Securities noted that the reopening of the U.S. government and the return of liquidity from the Federal Reserve could lead to a significant reversal of previous pessimistic trading assumptions. This may provide a larger rebound space for risk assets that had previously declined due to tightened liquidity [8] - The report suggests that the Hong Kong market, particularly the Hang Seng Technology Index, may benefit from this shift in liquidity, potentially leading to a strong rebound [8] - The current effective investment strategy is to maintain a positive yet cautious approach, focusing on balanced allocation and avoiding chasing high prices, while being vigilant about external factors such as U.S. Federal Reserve policies and U.S.-China relations [8]

Core Viewpoint - The pharmaceutical sector is experiencing active trading, with innovative drugs and biovaccines showing strong performance, indicating a positive outlook for the industry through 2026 [1] Industry Summary - The pharmaceutical sector has seen significant stock price increases, with companies like Chengda Pharmaceutical, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching a 20% limit up, while others like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also hit the limit up [1] - CITIC Securities forecasts that the investment trend in the pharmaceutical industry will continue to be driven by the concentration of innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices, leading to a stable domestic market environment [1] - The industry is expected to return to a market pricing system based on clinical value and demand, which will contribute to a stable and continuous growth trend in the performance of listed companies [1] Investment Strategy - The pharmaceutical industry is recommended for continued overweight positioning, with suggested investment themes for 2026 including: 1. Innovation-driven and internationalization, focusing on companies that are innovating and expanding internationally in a favorable domestic policy environment [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports due to geopolitical risks [1] 3. New policies and new opportunities, targeting companies benefiting from optimized procurement, medical insurance payment reforms, consumption stimulus policies, and state-owned enterprise reforms [1]